Tag: immunoprophylaxis
-
Beyfortus (Nirsevimab) Arrives in Malaysia to Shield Infants from RSV
Malaysia Approves Beyfortus (Nirsevimab) to Guard Infants Against RSV In a move welcomed by pediatric health advocates, Beyfortus (Nirsevimab), the preventive monoclonal antibody developed by Sanofi and AstraZeneca, has been approved by Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in infants. The approval…
-
Bronchiolitis and Beyfortus: Expanded indication for vulnerable children up to 24 months
Overview: Beyfortus and the fight against RSV bronchiolitis Bronchiolitis is a common respiratory illness in young children, most notably caused by the respiratory syncytial virus (RSV). Protecting vulnerable infants and toddlers from severe RSV infections has long been a priority for pediatric care teams. Beyfortus, the synthetic antibody nirsevimab developed by AstraZeneca and marketed by…